Advertisement

Click here for more guidelines.

 
 




CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2005; 46:737-738, doi:10.1016/j.jacc.2005.05.029 (Published online 27 July 2005).
© 2005 by the American College of Cardiology Foundation
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
j.jacc.2005.05.029v1
46/4/737    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gupta, V. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gupta, V. K.
Related Collections
Right arrowRelated Article

CORRESPONDENCE: LETTER TO THE EDITOR

Patent Foramen Ovale/Atrial Septal Defect Closure and Migraine: Searching the Rationale for the Procedure

Vinod Kumar Gupta, MD*

* Dubai Police Medical Services, P.O. Box 12005 Dubai United Arab Emirates (Email: docgupta{at}emirates.net.ae).


Azarbal et al. (1) studied closing patent foramen ovale (PFO) or atrial septal defect (ASD) for prophylaxis of migraine. The accompanying editorial highlights areas of caution (2). Additional concerns are: 1) Both right-to-left shunt (PFO) and left-to-right shunt (ASD) appear associated with migraine (3). 2) Closure of ASD improves left ventricular stroke volume; this physiological variable (3) might be involved in precipitating daily migraines. 3) Following ASD closure, plasma atrial natriuretic peptide levels would decrease (3). 4) Lateralization of headaches is a characteristic feature of migraine (4). With the concept of paradoxical embolization of gas, thrombi, or vasoactive neuromediators (2), these potential precipitants are presumed to be streamed regularly over decades to the same brain parenchymal site or circulatory segment in order to produce lateralizing headache (5). This is highly unlikely as paradoxical emboli are generally directed randomly. 5) Atenolol—a first-line migraine prophylactic—does not readily cross the blood-brain barrier (BBB) or significantly influence either brain neuronal function or circulation (4). 6) Drugs used to manage patients with migraine aura such as nifedipine, furosemide, and verapamil do not readily cross the intact BBB (6). These pharmacological absolutes challenge prevalent concepts of primary involvement of brain in migraine. 7) For a disease that can continue for decades, a follow-up period of 12 months (1) is rather short.

An explanation is required for the characteristic late appearance (in the teens or twenties) or disappearance (second and third trimesters of pregnancy and in later decades), in general, of migraine despite continued presence of PFO/ASD. Second, a high incidence of right-to-left shunt has been seen in cluster headache patients (42.5%, 17 of 40) (7). Cluster headache is a strictly lateralized primary headache; brain ischemia is not implicated in its pathogenesis. Third, migraine-with-aura patients seem to respond far better than migraine-without-aura patients (1). Headaches are less frequent, less severe, and shorter in migraine-with-aura patients. When the frequency of headache attacks is lessened, the possibility of the placebo effect in migraine trials is greater (5).

At this juncture, it is necessary to weigh carefully whether we need more reflection about the basic issues surrounding the apparent link between migraines and PFO/ASD or more clinical trials.


    References
 Top
 References
 
1. Azarbal B, Tobis J, Suh W, Chan V, Dao C, Gaster R. Association of interatrial shunts and migraine headaches. Impact of transcatheter closure J Am Coll Cardiol 2005;45:489-492.[Abstract/Free Full Text]

2. Tsimikas S. Transcatheter closure of patent foramen ovale for migraine prophylaxisHope or hype?. J Am Coll Cardiol 2005;45:496-498.[Free Full Text]

3. Gupta VK. Closure of atrial septal defect and migraine Headache 2004;44:291-292.[CrossRef][Web of Science][Medline]

4. Gupta VK. Non-lateralizing brain PET changes in migraine: phenomenology versus pharmacology? Brain 2004;127:E12.[Free Full Text]

5. Gupta VK. Percutaneous closure of patent foramen ovale reduces the frequency of migraine attacks Neurology 2004;63:1760-1761.[Free Full Text]

6. Gupta VK. Management of migraine aura: basic theoretical and clinical reconsiderations. Headache 2005. In press..

7. Finocchi C, Del Sette M, Angeli S, Rizzi D, Gandolfo C. Cluster headache and right-to-left shunt on contrast transcranial DopplerA case-control study. Neurology 2004;63:1309-1310.[Abstract/Free Full Text]


Related Article

Reply
Jonathan Tobis and Babak Azarbal
J. Am. Coll. Cardiol. 2005 46: 738-739. [Full Text] [PDF]




This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
j.jacc.2005.05.029v1
46/4/737    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gupta, V. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gupta, V. K.
Related Collections
Right arrowRelated Article

 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement